Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.

ABSTRACT:

Background

Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) as therapy for irAEs.

Methods

We performed a retrospective multicenter study evaluating patients diagnosed with de novo irAEs or flare of pre-existing autoimmune disease following ICI and were treated with anti-IL-6R. Our objectives were to assess the improvement of irAEs as well as the overall tumor response rate (ORR) before and after anti-IL-6R treatment.

Results

We identified a total of 92 patients who received therapeutic anti-IL-6R antibodies (tociliz

SUBMITTER: Fa'ak F 

PROVIDER: S-EPMC10277540 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature